NYSE:TEVA News 10 December 2025 - 12 January 2026

Teva shares rose about 4% to $33.29 after announcing a funding deal with Royalty Pharma worth up to $500 million for its experimental vitiligo drug. An SEC filing previewed Teva’s 2025 outlook, including projected revenue of $16.8–$17.0 billion and adjusted EBITDA of $4.8–$5.0 billion. Investors await more details at Tuesday’s J.P. Morgan Healthcare Conference.

Teva shares closed at $31.54 on Dec. 23, up 28% since Nov. 5, after S&P Global Ratings upgraded the company’s credit to ‘BB+’ on improved deleveraging. The stock traded near $31.93 pre-market Dec. 24. Analysts, including Piper Sandler, have raised price targets as Teva’s pipeline and biosimilars schedule gains clarity. Investors remain alert to pricing and patent risks.

December 10, 2025 – New York / Tel Aviv Teva Pharmaceutical Industries Limited (NYSE: TEVA; TASE: TEVA) is trading around its 52‑week highs as a wave of fresh news hits the stock: a new U.S. FDA filing for a once‑monthly schizophrenia drug, a string of bullish analyst upgrades, stronger long‑term cash‑flow guidance and notable institutional activity. At around $29 per share, Teva now carries a market capitalization of roughly $32–33 billion, with a 12‑month trading range of approximately $12.5 to just over $29.MarketBeat+2MarketBeat+2 Against that backdrop, investors are trying to decide whether TEVA is simply “priced for the pivot” or